Sector News

Pfizer to shut 55-year-old Mumbai manufacturing plant

July 15, 2015
Life sciences
Pfizer Ltd, the Indian unit of global pharmaceutical major Pfizer Inc., has decided to shut its manufacturing facility at Thane, near Mumbai, with effect from 16 September, the company said on Wednesday.
 
There has been no production activity at the plant since 2013, and the closure will not impact the supply of any of its medicines, according to company.
 
The decision to close the site is based on an assessment of its long-term viability and its ability to achieve the needed production, the statement said.
 
This Thane plant was commissioned in the 1960s. Pfizer had offered voluntary retirement scheme (VRS) to the workmen at the plant last year, which was taken up by as many as 132 of the 212 workmen, the company said.
 
The remaining 80 workmen continue to receive full wages, despite plant inactivity. As part of the closure process, the company will honour its obligations towards requisite compensation, as mandated by law, for the remaining workmen, it said.
 
Source: Live Mint

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach